# A Phase 2 Study of ABSK043 Combined With Osimertinib

> **NCT07710612** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Abbisko Therapeutics Co, Ltd** · enrollment: 72 (estimated)

## Conditions studied

- Non-Small Cell Lung Cancer With EGFR-mutated and PD-L1 Positive

## Interventions

- **DRUG:** ABSK043 in combination with Osimertinib

## Key facts

- **NCT ID:** NCT07710612
- **Lead sponsor:** Abbisko Therapeutics Co, Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08-31
- **Primary completion:** 2029-12-31
- **Final completion:** 2030-12-31
- **Target enrollment:** 72 (ESTIMATED)
- **Last updated:** 2026-07-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07710612

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07710612, "A Phase 2 Study of ABSK043 Combined With Osimertinib". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07710612. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*